Skip to content

A multicenter, randomized study on herbal soup and Chinese medicine powder in improving eradication rate and reducing recurrence rate of Helicobacter Pylori based on standard triple therapy.

Study of prevention and treatment of Traditional Chinese Medicine of chronic gastritis and application of standard

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001212
Enrollment
Unknown
Registered
2011-03-09
Start date
2011-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Gastritis

Interventions

A:omeprazole 20mg, amoxicillin 1.0, clarithromycin 0.5,Bid(10 days)
B:A+Chinese medicine powder 2 weeks (6g,Bid)
C:A+herbal soup 2 weeks(150ml,Tid)
D:A+herbal soup 4 weeks(150ml,Tid)

Sponsors

Xiyuan Hospital affiliated to China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet diagnostic criteria of Chronic Gastritis(chronic superficial gastritis and chronic atrophic gastritis); 2. To be aged is between 18-65 years old; 3. The result of Helicobacter Pylori testing by over two different principles positive(PPI, H2PA, Bismuth and antibiotics were forbidden two weeks before testing); 4. Local permanent residents, informed consent and accept corresponding treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with chronic atrophic gastritis accompany with severe dysplasia, upper gastrointestinal hemorrhage, peptic ulcer, gastroenteric tumor; 2. Patients with Gastrointestinal organic diseases(suan as chronic pancreatitis, hepatic cirrhosis etc) or systemic diseases which can affect gastrointestinal power(such as hyperthyroidism, diabetes mellitus, chronic renal insufficiency, mental diseases and nerve system diseases etc); 3. Patients with severe heart, hepatic, renal diseases, hematopoietic diseases, and tumor; 4. Patients had used drugs(antiacid, H2RA, PPI, Bismuth and antibiotics) in two weeks which could affect the result of HP testing; 5. Pregnant and Lactating women; 6. With the history of metal or nerve system diseases; 7. With the history of allergic reaction to used drugs; 8. Patients who are taking part in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Eradication rate of HP;

Secondary

MeasureTime frame
Recurrence rate of HP in one year;PRO scale scores;

Countries

China

Contacts

Public ContactXudong Tang
txdly@sina.com+86 10 62835001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026